What is the current size and annual growth rate of the optic neuropathy management market?
The optic neuropathy management market size has grown strongly in recent years. It will grow from $3.62 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to the rising prevalence of optic neuropathy, the rising number of eye injuries, the increase in their investment in eye care services, the increasing demand for specialized eye care services, the rising incidence of diabetes, and other chronic diseases.
The optic neuropathy management market size is expected to see strong growth in the next few years. It will grow to $4.85 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to the growing number of individuals afflicted by amebic infections, increasing geriatric population, increasing prevalence of optic neuritis, growing incidence of glaucoma, and increased prevalence rate of optic neuritis. Major trends in the forecast period include advancements in medical technology, personalized medicine and telemedicine, technological advancements in diagnostic techniques, expansion of healthcare infrastructure in emerging markets, and a focus on neuroprotective therapies.
Get Your Free Sample of The Global Optic Neuropathy Management Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21236&type=smp
Which major factors have contributed to the expansion of the optic neuropathy management market?
The rise in the prevalence of eye disease is expected to propel the growth of the optic neuropathy management market going forward. Eye disease refers to any condition that affects the structure or function of the eyes, leading to impaired vision or other related symptoms. The rise in the prevalence of eye disease is driven by aging populations, increased screen time, poor lifestyle choices, and underlying health conditions such as diabetes. Optic neuropathy management helps reduce the prevalence of eye disease by preventing further optic nerve damage and preserving vision. For instance, in February 2025, according to the Department of Health and Social Care, a UK-based government department, approximately 2 million people in the UK are living with some degree of sight loss, with this number expected to increase to 2.7 million by 2030. Therefore, the rise in the prevalence of eye disease is driving the growth of the optic neuropathy management market.
How is the optic neuropathy management market segmented?
The optic neuropathy management market covered in this report is segmented –
1) By Treatment Type: Medications, Surgery, Other Treatment Types
2) By Diagnosis: Imaging Tests, Blood Tests, Other Diagnosis
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Medications: Corticosteroids, Neuroprotective Agents, Antioxidants, Immunosuppressants, Prostaglandin Analogs
2) By Surgery: Optic Nerve Decompression Surgery, Optic Nerve Transplantation, Retinal Implant Surgery
3) By Other Treatment Types: Low Vision Aids, Stem Cell Therapy, Gene Therapy
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/optic-neuropathy-management-global-market-report
Who are the top competitors in the optic neuropathy management market?
Major companies operating in the optic neuropathy management market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc, Santen Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals, Aerie Pharmaceuticals, Neurophth Therapeutics, AdvaCare.
Which key trends are expected to influence the optic neuropathy management market in the coming years?
Major companies operating in the optic neuropathy management market are concentrating on developing innovative therapies, such as monoclonal antibody therapy, to achieve a competitive advantage. Monoclonal antibodies are laboratory-made proteins designed to mimic the immune system’s ability to fight harmful pathogens such as viruses and bacteria. For instance, in March 2023, Horizon Therapeutics, an Ireland-based company, presented a new analysis of MRI findings for their drug, UPLIZNA (inebilizumab). The analysis demonstrated that UPLIZNA reduces the formation of asymptomatic optic nerve lesions in individuals with neuromyelitis optica spectrum disorder (NMOSD). This highlights Horizon’s commitment to offering innovative treatments for rare diseases such as NMOSD, gout, and thyroid eye disease. UPLIZNA is a monoclonal antibody designed to treat NMOSD by targeting and depleting harmful B cells, reducing inflammation, and preventing further damage to the central nervous system and optic nerves, ultimately reducing relapses and preserving vision.
Which regional trends are influencing the optic neuropathy management market, and which area dominates the industry?
North America was the largest region in the optic neuropathy management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the optic neuropathy management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Optic Neuropathy Management Market Report 2025 Offer?
The optic neuropathy management market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Optic neuropathy management refers to the diagnosis, treatment, and monitoring of optic nerve damage using medications, lifestyle modifications, surgical interventions, and vision rehabilitation to prevent further deterioration and improve visual function.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21236
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
